Pathstone Family Office LLC raised its position in Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) by 307.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 125,704 shares of the company’s stock after purchasing an additional 94,878 shares during the period. Pathstone Family Office LLC owned about 0.06% of Hims & Hers Health worth $701,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Captrust Financial Advisors lifted its holdings in Hims & Hers Health by 1,827.4% in the 1st quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock valued at $36,000 after purchasing an additional 6,414 shares in the last quarter. Lazard Asset Management LLC purchased a new position in shares of Hims & Hers Health during the 3rd quarter worth about $51,000. Tower Research Capital LLC TRC lifted its holdings in shares of Hims & Hers Health by 70.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 9,538 shares of the company’s stock worth $54,000 after acquiring an additional 3,933 shares during the period. FNY Investment Advisers LLC purchased a new position in shares of Hims & Hers Health during the 3rd quarter worth about $66,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Hims & Hers Health by 61.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,539 shares of the company’s stock worth $81,000 after acquiring an additional 5,524 shares during the period. 45.60% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on HIMS. Truist Financial increased their price objective on shares of Hims & Hers Health from $7.00 to $12.00 and gave the stock a “hold” rating in a report on Tuesday, February 28th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $7.00 to $9.00 in a report on Wednesday, March 1st. Citigroup increased their price objective on shares of Hims & Hers Health from $9.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, February 28th. Jefferies Financial Group raised shares of Hims & Hers Health from a “hold” rating to a “buy” rating and increased their target price for the stock from $7.00 to $11.00 in a research report on Thursday, February 9th. Finally, Bank of America increased their target price on shares of Hims & Hers Health from $11.50 to $13.50 and gave the stock a “buy” rating in a research report on Tuesday, February 28th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $11.55.
Hims & Hers Health Stock Down 0.9 %
Hims & Hers Health (NYSE:HIMS – Get Rating) last issued its quarterly earnings data on Monday, February 27th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. Hims & Hers Health had a negative net margin of 12.47% and a negative return on equity of 20.69%. The company had revenue of $167.30 million during the quarter, compared to the consensus estimate of $161.18 million. During the same quarter last year, the company earned ($0.11) earnings per share. Hims & Hers Health’s revenue for the quarter was up 97.5% on a year-over-year basis. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post -0.13 earnings per share for the current year.
Insider Buying and Selling at Hims & Hers Health
In other news, insider Soleil Boughton sold 4,837 shares of the stock in a transaction that occurred on Friday, December 16th. The stock was sold at an average price of $6.74, for a total transaction of $32,601.38. Following the completion of the transaction, the insider now directly owns 315,178 shares in the company, valued at approximately $2,124,299.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director Lynne Chou O’keefe sold 10,044 shares of the stock in a transaction that occurred on Monday, December 19th. The stock was sold at an average price of $6.72, for a total transaction of $67,495.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 4,837 shares of the stock in a transaction that occurred on Friday, December 16th. The shares were sold at an average price of $6.74, for a total value of $32,601.38. Following the transaction, the insider now owns 315,178 shares of the company’s stock, valued at $2,124,299.72. The disclosure for this sale can be found here. Insiders sold 682,625 shares of company stock valued at $7,381,157 over the last 90 days. 35.22% of the stock is owned by corporate insiders.
About Hims & Hers Health
Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.
Read More
- Get a free copy of the StockNews.com research report on Hims & Hers Health (HIMS)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
